23 assets in Urinary Bladder Cancer

Therapeutic assets addressing Urinary Bladder Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Urinary Bladder Cancer	National Cancer Institute (NCI)	P2	BB (66)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Urinary Bladder Cancer	Fred Hutchinson Cancer Center	P2	BB (66)
Carboplatin Urinary Bladder Cancer	Iambic Therapeutics, Inc	P2	BB (64)
Pembrolizumab Urinary Bladder Cancer	Fred Hutchinson Cancer Center	P2	BB (64)
Trastuzumab Urinary Bladder Cancer	Iambic Therapeutics, Inc	P2	BB (64)
Nivolumab Urinary Bladder Cancer	M.D. Anderson Cancer Center	P2	B (63)
Cabozantinib Urinary Bladder Cancer	National Cancer Institute (NCI)	P2	B (60)
Cis-Diamminedichloroplatinum Ii Urinary Bladder Cancer	G1 Therapeutics, Inc.	P2	B (60)
Ipilimumab Urinary Bladder Cancer	M.D. Anderson Cancer Center	P2	B (59)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Urinary Bladder Cancer	National Cancer Institute (NCI)	P2	B (58)
Apsolol Urinary Bladder Cancer	Emory University	P2	CCC (53)
Avelumab Urinary Bladder Cancer	G1 Therapeutics, Inc.	P2	CCC (53)
Eribulin Monomethanesulfonate Urinary Bladder Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Relatlimab Urinary Bladder Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Tocilizumab Urinary Bladder Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Quemliclustat Urinary Bladder Cancer	Fred Hutchinson Cancer Center	P1/2	CCC (48)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells Urinary Bladder Cancer	USWM CT, LLC	P1	CC (43)
Docetaxel Urinary Bladder Cancer	Jonsson Comprehensive Cancer Center	P1	CC (43)
Etoposide Urinary Bladder Cancer	Jonsson Comprehensive Cancer Center	P1	CC (43)
Hafnium Oxide Urinary Bladder Cancer	Nanobiotix	P1	CC (43)
iam1363 Urinary Bladder Cancer	Iambic Therapeutics, Inc	P1	CC (43)
Tiragolumab Urinary Bladder Cancer	Centre Georges Francois Leclerc	P1	CC (43)
esg401 Urinary Bladder Cancer	Shanghai Escugen Biotechnology Co., Ltd	P1/2	NR ()